SH PHARMA2607.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, SH PHARMA (2607.HK) trades at a P/E of 7.48x, P/B of 0.71x, P/S of 0.12x, and a dividend yield of 4.66%.
Longitudinal percentile comparison: P/E sits at the 29th percentile over the trailing 10Y window (vs. 39th percentile over 3Y); P/B sits at the 2nd percentile over the trailing 10Y window (vs. 6th percentile over 3Y); P/S sits at the 1st percentile over the trailing 10Y window (vs. 4th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 18th percentile within its industry and the 33rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.66%, ranking at the 94th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 27.0 points — relying on either metric alone could be misleading. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. SH PHARMA operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2607 · SEHK: 2607 · 2607
Want the full picture on whether SH PHARMA (2607.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 7.48 | ||||||
| P/B (MRQ) | 0.71 | ||||||
| P/S (TTM) | 0.12 | ||||||
| Dividend Yield | 4.66% | ||||||
| Buyback + Div Yield | 4.66% |